ImmunoGen Inc., of Waltham, Mass., said it started a Phase I trial of IMGN853, a TAP (Targeted Antibody Payload) compound comprising an FOLR1-targeting antibody attached to cell-killing agent DM4, in patients with ovarian cancer or other solid tumors that overexpress FOLR1, including non-small-cell lung cancer. Once the maximum-tolerated dose is established, the activity of the compound will be evaluated in disease-specific patient cohorts.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter